The B. Riley Securities Healthcare Equity Research Team is
hosting a Radiation Oncology Investor Day on February 22, 2022, to provide
insights into the current state and future direction of the radiation oncology
field by bringing together innovative companies and independent experts. Senior
oncology-focused analyst and trained radiochemist Justin Walsh, PhD, will
conduct fireside chats with key public and private companies working in the
space, as well as an expert KOL panel discussion. Topics are expected to range
from understanding and overcoming supply chain and logistical challenges unique
to radiopharmaceuticals, to the potential competitive and/or complementary
roles of external beam and targeted radiotherapies.
"While external beam radiation therapy has remained at the
forefront of cancer treatment for over a century, recent innovations in
precision/targeted medicine and next-generation medical devices have advanced
the field to the point where patients are beginning to see significant
improvements in outcomes," remarked Justin Walsh. "With sustained interest and
investment from Big Pharma and the success of approved/late-stage
radiopharmaceuticals, we believe that the field is poised to benefit patents
across cancer indications and look forward to highlighting innovators who have
made it their mission to ensure this occurs."
Expert Panel Discussion: "Expanding Opportunities In Radiation
Oncology - From Reactor To Bedside"
Featuring panel participants: Ravi Patel, MD, PhD (assistant
professor, University of Pittsburgh School of Medicine, and radiation
oncologist at UPMC Hillman Cancer Center), Kevin Staton, MBA (Head of Project
Management at Evergreen Theragnostics), & Leila Safavi (PhD, CEO and
Co-Founder of Purist Inc.)
The following list of companies
participating in fireside chats is current as of today's date and may be
subject to change:
·
Actinium Pharmaceuticals, Inc. (ATNM)
·
Alpha Tau Medical
·
Fusion Pharmaceuticals (FUSN)
·
GT Medical Technologies
·
Oncoinvent A/S
·
POINT Biopharma Global Inc. (PNT)
·
Viewpoint Molecular Targeting, Inc.
This invitation-only virtual event is reserved for clients
of the firm. Interested participants should contact their B. Riley representative.
For more information, visit www.brileysecurities.com.
To view our upcoming events, visit www.brileyfin.com/events or view our LinkedIn page.
About B. Riley Securities
B. Riley Securities provides a full suite of investment
banking, corporate finance, advisory, research, and sales and trading services.
Investment banking services include initial, secondary and follow-on offerings,
institutional private placements, merger and acquisition (M&A) advisory,
SPACs, corporate restructuring and recapitalization. B. Riley is nationally
recognized and highly ranked for its proprietary small-cap equity research. The
firm is a wholly owned subsidiary of B. Riley Financial. Please see www.brileyfin.com/disclosures for
disclosures about B. Riley Securities Research.
B. Riley Financial provides collaborative solutions tailored
to fit the capital raising and business advisory needs of its clients and
partners. B. Riley operates through several subsidiaries that offer a diverse
range of complementary end-to-end capabilities spanning investment banking and
institutional brokerage, private wealth and investment management, financial
consulting, corporate restructuring, operations management, risk and
compliance, due diligence, forensic accounting, litigation support, appraisal
and valuation, auction and liquidation services. For more information, please
visit www.brileyfin.com.
Contacts
Event Inquiries
Jolene Glasser
(818) 746-9524
Media Inquiries
Jo Anne McCusker
(646) 885-5425